{"protocolSection": {"identificationModule": {"nctId": "NCT01106690", "orgStudyIdInfo": {"id": "CR017032"}, "secondaryIdInfos": [{"id": "28431754DIA3012", "type": "OTHER", "domain": "Janssen Research & Development, LLC"}], "organization": {"fullName": "Janssen Research & Development, LLC", "class": "INDUSTRY"}, "briefTitle": "The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy"}, "statusModule": {"statusVerifiedDate": "2013-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-06"}, "primaryCompletionDateStruct": {"date": "2011-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-04-01", "studyFirstSubmitQcDate": "2010-04-16", "studyFirstPostDateStruct": {"date": "2010-04-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-04-02", "resultsFirstSubmitQcDate": "2013-04-02", "resultsFirstPostDateStruct": {"date": "2013-05-21", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-03-30", "dispFirstSubmitQcDate": "2012-04-24", "dispFirstPostDateStruct": {"date": "2012-04-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-06-26", "lastUpdatePostDateStruct": {"date": "2013-07-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Janssen Research & Development, LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receving treatment with metformin and pioglitazone and have inadequate glycemic (blood sugar) control.", "detailedDescription": "Canagliflozin is a drug that is being tested to see if it may be useful in treating patients diagnosed with type 2 diabetes mellitus (T2DM). This is a randomized (study drug assigned by chance), double-blind (neither the patient or the study doctor will know the name of the assigned treatment), parallel-group, 3-arm (3 treatment groups) multicenter study to determine the efficacy, safety, and tolerability of canagliflozin (100 mg and 300 mg) compared to placebo (a capsule that looks like all the other treatments but has no real medicine) in patients with T2DM who are not achieving an adequate response from current antihyperglycemic therapy with metformin and pioglitazone to control their diabetes. Approximately 360 patients with T2DM who are receiving combination therapy with metformin and pioglitazone will receive the addition of once-daily treatment with canagliflozin (100 mg or 300 mg) or placebo capsules for 26 weeks followed by a 26-week extension period where patients treated with canagliflozin (100 mg or 300 mg) will continue treatment for an additional 26 weeks and patients treated with placebo will be switched to active double-blind treatment with sitagliptin 100 mg, an antihyperglycemic agent administered once-daily for 26 weeks. In addition, all patients will take protocol specified stable doses of metformin and pioglitazone along with assigned study drug for the duration of the study. Patients will participate in the study for approximately 59 to 78 weeks. During the study, if a patient's fasting blood sugar remains high despite treatment with study drug, the patient will receive treatment with glimepiride (rescue therapy) in accordance with local prescribing information. During treatment, patients will be monitored for safety by review of adverse events, results from laboratory tests, 12-lead electrocardiograms (ECGs), vital signs measurements, body weight, physical examinations, and self-monitored blood glucose (SMGB) measurements. The primary outcome measure in the study is the effect of canagliflozin relative to placebo on hemoglobin A1c (HbA1c) after 26 weeks of treatment. Study drug will be taken orally (by mouth) once daily before the first meal each day unless otherwise specified. Patients will take single-blind placebo capsules for 2 weeks before randomization. After randomization, patients will take double-blind canagliflozin (100 mg or 300 mg) for 52 weeks OR placebo for 26 weeks switched to double-blind sitagliptin 100 mg for 26 weeks."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Canagliflozin", "Placebo", "Sitagliptin (Januvia)", "Metformin", "Pioglitazone (Actos)", "Hemoglobin A1c", "Type 2 diabetes mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 344, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo/Sitagliptin", "type": "OTHER", "description": "Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.", "interventionNames": ["Drug: Placebo", "Drug: Sitagliptin", "Drug: Metformin", "Drug: Pioglitazone"]}, {"label": "Canagliflozin 100 mg", "type": "EXPERIMENTAL", "description": "Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.", "interventionNames": ["Drug: Canagliflozin", "Drug: Metformin", "Drug: Pioglitazone"]}, {"label": "Canagliflozin 300 mg", "type": "EXPERIMENTAL", "description": "Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.", "interventionNames": ["Drug: Canagliflozin", "Drug: Metformin", "Drug: Pioglitazone"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.", "armGroupLabels": ["Placebo/Sitagliptin"]}, {"type": "DRUG", "name": "Canagliflozin", "description": "One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.", "armGroupLabels": ["Canagliflozin 100 mg", "Canagliflozin 300 mg"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.", "armGroupLabels": ["Placebo/Sitagliptin"]}, {"type": "DRUG", "name": "Metformin", "description": "The patient's stable dose of metformin background therapy should be continued throughout the study.", "armGroupLabels": ["Canagliflozin 100 mg", "Canagliflozin 300 mg", "Placebo/Sitagliptin"]}, {"type": "DRUG", "name": "Pioglitazone", "description": "The patient's stable dose of pioglitazone background therapy should be continued throughout the study.", "armGroupLabels": ["Canagliflozin 100 mg", "Canagliflozin 300 mg", "Placebo/Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in HbA1c From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "timeFrame": "Day 1 (Baseline) and Week 26"}], "secondaryOutcomes": [{"measure": "Percentage of Patients With HbA1c <7% at Week 26", "description": "The table below shows the percentage of patients with HbA1c\\<7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.", "timeFrame": "Week 26"}, {"measure": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "timeFrame": "Day 1 (Baseline) and Week 26"}, {"measure": "Change in Homeostasis Model Assessment (HOMA2-%B) From Baseline to Week 26", "description": "HOMA2-%B is a measure of beta cell function (the cells in the pancreas that produce and store insulin). The table below shows the least-squares (LS) mean change in HOMA2-%B from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "timeFrame": "Day 1 (Baseline) and Week 26"}, {"measure": "Percent Change in Body Weight From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.", "timeFrame": "Day 1 (Baseline) and Week 26"}, {"measure": "Change in Systolic Blood Pressure (SBP) From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "timeFrame": "Day 1 (Baseline) and Week 26"}, {"measure": "Percent Change in Triglycerides From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.", "timeFrame": "Day 1 (Baseline) and Week 26"}, {"measure": "Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.", "timeFrame": "Day 1 (Baseline) and Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* All patients must have a diagnosis of T2DM and be currently treated with PPAR gamma agent ((pioglitazone or rosiglitazone) and another anti-diabetes agent (metformin)\n* Patients in the study must have a HbA1c between \\>=7 and \\<=10.5% and a fasting plasma glucose (FPG) \\<270 mg/dL (15 mmol/L)\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy\n* or a severe hypoglycemic episode within 6 months before screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Janssen Research & Development, LLC C. Clinical Trial", "affiliation": "Janssen Research & Development, LLC", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Anniston", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.65983, "lon": -85.83163}}, {"city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"city": "Tucson", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"city": "Little Rock", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"city": "Burlingame", "state": "California", "country": "United States", "geoPoint": {"lat": 37.5841, "lon": -122.36608}}, {"city": "Encinitas", "state": "California", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"city": "Fullerton", "state": "California", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"city": "Roseville", "state": "California", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"city": "Santa Ana", "state": "California", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"city": "Wes Hills", "state": "California", "country": "United States", "geoPoint": {"lat": 34.19731, "lon": -118.64398}}, {"city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"city": "Bartow", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.89641, "lon": -81.84314}}, {"city": "Hollywood", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"city": "Jacksonville", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"city": "Pembroke Pines", "state": "Florida", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"city": "Des Moines", "state": "Iowa", "country": "United States", "geoPoint": {"lat": 41.60054, "lon": -93.60911}}, {"city": "Baton Rouge", "state": "Louisiana", "country": "United States", "geoPoint": {"lat": 30.45075, "lon": -91.15455}}, {"city": "Chaska", "state": "Minnesota", "country": "United States", "geoPoint": {"lat": 44.78941, "lon": -93.60218}}, {"city": "Picayune", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 30.52556, "lon": -89.67788}}, {"city": "Billings", "state": "Montana", "country": "United States", "geoPoint": {"lat": 45.78329, "lon": -108.50069}}, {"city": "Charlotte", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"city": "Hickory", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.73319, "lon": -81.3412}}, {"city": "Raleigh", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"city": "Dublin", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 40.09923, "lon": -83.11408}}, {"city": "Perrysburg", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.557, "lon": -83.62716}}, {"city": "Tulsa", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"city": "Yukon", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.50672, "lon": -97.76254}}, {"city": "Bensalem", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.10455, "lon": -74.95128}}, {"city": "Bristol", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"city": "Kingsport", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"city": "Nashville", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"city": "Arlington", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "Grand Prairie", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.74596, "lon": -96.99778}}, {"city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"city": "New Braunfels", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"city": "Falls Church", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"city": "Virginia Beach", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 36.85293, "lon": -75.97799}}, {"city": "Federal Way", "state": "Washington", "country": "United States", "geoPoint": {"lat": 47.32232, "lon": -122.31262}}, {"city": "Selah", "state": "Washington", "country": "United States", "geoPoint": {"lat": 46.65402, "lon": -120.53007}}, {"city": "Bathurst", "state": "New Brunswick", "country": "Canada", "geoPoint": {"lat": 47.61814, "lon": -65.65112}}, {"city": "Moncton", "state": "New Brunswick", "country": "Canada", "geoPoint": {"lat": 46.09454, "lon": -64.7965}}, {"city": "Grand Falls-Windsor", "state": "Newfoundland and Labrador", "country": "Canada", "geoPoint": {"lat": 48.93324, "lon": -55.66492}}, {"city": "Brampton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.68341, "lon": -79.76633}}, {"city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"city": "Ottawa", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"city": "Smiths Falls", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 44.90452, "lon": -76.02333}}, {"city": "Thornhill", "state": "Ontario", "country": "Canada"}, {"city": "Drummondville", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.88336, "lon": -72.48241}}, {"city": "Calgary", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"city": "Mount Pearl", "country": "Canada", "geoPoint": {"lat": 47.51659, "lon": -52.78135}}, {"city": "Truro", "country": "Canada", "geoPoint": {"lat": 45.36685, "lon": -63.26538}}, {"city": "Kuopio", "country": "Finland", "geoPoint": {"lat": 62.89238, "lon": 27.67703}}, {"city": "Oulu", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"city": "Turku", "country": "Finland", "geoPoint": {"lat": 60.45148, "lon": 22.26869}}, {"city": "Bondy Cedex", "country": "France", "geoPoint": {"lat": 48.9018, "lon": 2.48931}}, {"city": "Le Creusot", "country": "France", "geoPoint": {"lat": 46.80714, "lon": 4.41632}}, {"city": "Narbonne Cedex", "country": "France", "geoPoint": {"lat": 43.18396, "lon": 3.00141}}, {"city": "Aschaffenburg", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"city": "Mainz", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"city": "Neuwied", "country": "Germany", "geoPoint": {"lat": 50.4336, "lon": 7.47057}}, {"city": "Schkeuditz", "country": "Germany", "geoPoint": {"lat": 51.39678, "lon": 12.22141}}, {"city": "Athens", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"city": "Thessalonikis", "country": "Greece"}, {"city": "Thessaloniki", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"city": "Ahmedabad", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"city": "Belgaum", "country": "India", "geoPoint": {"lat": 15.85212, "lon": 74.50447}}, {"city": "Chennai", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"city": "Coimbatore", "country": "India", "geoPoint": {"lat": 11.00555, "lon": 76.96612}}, {"city": "Jaipur", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"city": "Nagpur", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"city": "Chihuahua", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"city": "Ciudad Juarez", "country": "Mexico", "geoPoint": {"lat": 31.72024, "lon": -106.46084}}, {"city": "Durango", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"city": "Almer\u00eda", "country": "Spain", "geoPoint": {"lat": 36.83814, "lon": -2.45974}}, {"city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"city": "Sevilla", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"city": "Bangkok", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"city": "Khon Kaen", "country": "Thailand", "geoPoint": {"lat": 16.44671, "lon": 102.833}}, {"city": "Antrim", "country": "United Kingdom", "geoPoint": {"lat": 54.7, "lon": -6.2}}, {"city": "Belfast", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}]}, "referencesModule": {"references": [{"pmid": "28327140", "type": "DERIVED", "citation": "Davies MJ, Merton K, Vijapurkar U, Yee J, Qiu R. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovasc Diabetol. 2017 Mar 21;16(1):40. doi: 10.1186/s12933-017-0517-7."}, {"pmid": "28241822", "type": "DERIVED", "citation": "Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017 Feb 27;16(1):29. doi: 10.1186/s12933-017-0511-0."}, {"pmid": "28197834", "type": "DERIVED", "citation": "Gilbert RE, Mende C, Vijapurkar U, Sha S, Davies MJ, Desai M. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. Diabetes Ther. 2017 Apr;8(2):451-458. doi: 10.1007/s13300-017-0232-0. Epub 2017 Feb 14."}, {"pmid": "27977934", "type": "DERIVED", "citation": "Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-562. doi: 10.1080/03007995.2016.1271780. Epub 2017 Jan 4."}, {"pmid": "27600862", "type": "DERIVED", "citation": "John M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. Int J Clin Pract. 2016 Sep;70(9):775-85. doi: 10.1111/ijcp.12868."}, {"pmid": "26580237", "type": "DERIVED", "citation": "Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18."}, {"pmid": "26373629", "type": "DERIVED", "citation": "Blonde L, Woo V, Mathieu C, Yee J, Vijapurkar U, Canovatchel W, Meininger G. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Curr Med Res Opin. 2015 Nov;31(11):1993-2000. doi: 10.1185/03007995.2015.1082991. Epub 2015 Sep 28."}, {"pmid": "26121561", "type": "DERIVED", "citation": "Gavin JR 3rd, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(9):1693-702. doi: 10.1185/03007995.2015.1067192. Epub 2015 Sep 4."}, {"pmid": "25813214", "type": "DERIVED", "citation": "Cefalu WT, Stenlof K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015 Jun;58(6):1183-7. doi: 10.1007/s00125-015-3547-2. Epub 2015 Mar 27."}, {"pmid": "25329038", "type": "DERIVED", "citation": "Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, Meininger G. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82. doi: 10.1111/jch.12425. Epub 2014 Oct 20."}, {"pmid": "24918789", "type": "DERIVED", "citation": "Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014 May;126(3):16-34. doi: 10.3810/pgm.2014.05.2753."}, {"pmid": "24786834", "type": "DERIVED", "citation": "Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014 Sep;30(9):1759-68. doi: 10.1185/03007995.2014.919907. Epub 2014 May 22."}, {"pmid": "24742013", "type": "DERIVED", "citation": "Sinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A, Shaw W, Usiskin K, Desai M, Meininger G. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014 Apr 18;14:37. doi: 10.1186/1472-6823-14-37."}, {"pmid": "24517339", "type": "DERIVED", "citation": "Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "344 patients were randomly allocated to the 3 treatment arms. 342 patients received at least 1 dose of study drug and were included in the modified intent-to-treat (mITT) analysis set (used for the Week 26 efficacy analysis) and safety analysis set (used for the Week 26 and Week 52 safety analyses).", "recruitmentDetails": "This study evaluated the efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin and pioglitazone. The study was conducted between 13 April 2010 and 20 November 2011 and recruited patients from 74 study centers in 11 countries worldwide.", "groups": [{"id": "FG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "FG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "FG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "periods": [{"title": "Core Period: Baseline to Week 26", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "115"}, {"groupId": "FG001", "numSubjects": "113"}, {"groupId": "FG002", "numSubjects": "114"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "91"}, {"groupId": "FG001", "numSubjects": "104"}, {"groupId": "FG002", "numSubjects": "101"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Creatinine or eGFR withdrawal criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Noncompliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Unable to take rescue therapy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lack of efficacy on rescue therapy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "6"}]}]}, {"title": "Extension Period: Week 26 to Week 52", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "1 pt completed core but did not enter ext: physician decision(1).", "numSubjects": "90"}, {"groupId": "FG001", "comment": "1 pt completed core but did not enter ext: physician decision(1).", "numSubjects": "103"}, {"groupId": "FG002", "comment": "5 pts completed core but did not exter ext: lost to f/u(1), not spec(2), AE(1), eGFR criteria(1).", "numSubjects": "96"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "78"}, {"groupId": "FG001", "numSubjects": "96"}, {"groupId": "FG002", "numSubjects": "89"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Noncompliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Unable to take rescue therapy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "BG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "BG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "115"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "114"}, {"groupId": "BG003", "value": "342"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "83"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "83"}, {"groupId": "BG003", "value": "249"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "93"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.3", "spread": "9.56"}, {"groupId": "BG001", "value": "56.7", "spread": "10.36"}, {"groupId": "BG002", "value": "57", "spread": "10.19"}, {"groupId": "BG003", "value": "57.4", "spread": "10.03"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "51"}, {"groupId": "BG003", "value": "126"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "77"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "216"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "CANADA", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "67"}]}]}, {"title": "FINLAND", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "13"}]}]}, {"title": "FRANCE", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}]}, {"title": "GERMANY", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "19"}]}]}, {"title": "GREECE", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "INDIA", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "25"}]}]}, {"title": "MEXICO", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "21"}]}]}, {"title": "SPAIN", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "15"}]}]}, {"title": "THAILAND", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "17"}]}]}, {"title": "UNITED KINGDOM", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "8"}]}]}, {"title": "UNITED STATES", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "154"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in HbA1c From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "populationDescription": "Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "Day 1 (Baseline) and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "112"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.26", "spread": "0.069"}, {"groupId": "OG001", "value": "-0.89", "spread": "0.069"}, {"groupId": "OG002", "value": "-1.03", "spread": "0.070"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-0.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.811", "ciUpperLimit": "-0.437", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.095"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.951", "ciUpperLimit": "-0.575", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.096"}]}, {"type": "SECONDARY", "title": "Percentage of Patients With HbA1c <7% at Week 26", "description": "The table below shows the percentage of patients with HbA1c\\<7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.", "populationDescription": "Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "112"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.5"}, {"groupId": "OG001", "value": "46.9"}, {"groupId": "OG002", "value": "64.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.007", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.40", "ciPctValue": "95", "ciLowerLimit": "1.26", "ciUpperLimit": "4.57"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "5.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.73", "ciUpperLimit": "10.60"}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "populationDescription": "Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Day 1 (Baseline) and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "112"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.54", "spread": "2.785"}, {"groupId": "OG001", "value": "-26.8", "spread": "2.796"}, {"groupId": "OG002", "value": "-33.2", "spread": "2.817"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-29.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-36.96", "ciUpperLimit": "-21.78", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.857"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-35.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-43.30", "ciUpperLimit": "-28.11", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.861"}]}, {"type": "SECONDARY", "title": "Change in Homeostasis Model Assessment (HOMA2-%B) From Baseline to Week 26", "description": "HOMA2-%B is a measure of beta cell function (the cells in the pancreas that produce and store insulin). The table below shows the least-squares (LS) mean change in HOMA2-%B from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "populationDescription": "Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "HOMA2-%B", "timeFrame": "Day 1 (Baseline) and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "105"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "spread": "1.833"}, {"groupId": "OG001", "value": "15.19", "spread": "1.809"}, {"groupId": "OG002", "value": "18.14", "spread": "1.790"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "14.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.315", "ciUpperLimit": "19.236", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.521"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "17.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "12.293", "ciUpperLimit": "22.166", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.509"}]}, {"type": "SECONDARY", "title": "Percent Change in Body Weight From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.", "populationDescription": "Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent change", "timeFrame": "Day 1 (Baseline) and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "112"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.3"}, {"groupId": "OG001", "value": "-2.8", "spread": "0.3"}, {"groupId": "OG002", "value": "-3.8", "spread": "0.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-2.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.6", "ciUpperLimit": "-1.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-3.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.6", "ciUpperLimit": "-2.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.4"}]}, {"type": "SECONDARY", "title": "Change in Systolic Blood Pressure (SBP) From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.", "populationDescription": "Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Day 1 (Baseline) and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "112"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.24", "spread": "1.033"}, {"groupId": "OG001", "value": "-5.30", "spread": "1.036"}, {"groupId": "OG002", "value": "-4.70", "spread": "1.044"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.005", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-4.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.879", "ciUpperLimit": "-1.251", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.430"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.016", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-3.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.281", "ciUpperLimit": "-0.643", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.433"}]}, {"type": "SECONDARY", "title": "Percent Change in Triglycerides From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.", "populationDescription": "Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent change", "timeFrame": "Day 1 (Baseline) and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "108"}, {"groupId": "OG002", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.2", "spread": "4.1"}, {"groupId": "OG001", "value": "3.2", "spread": "4.1"}, {"groupId": "OG002", "value": "-1.7", "spread": "4.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.034", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-12.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.1", "ciUpperLimit": "-0.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.7"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "-16.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.1", "ciUpperLimit": "-5.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.7"}]}, {"type": "SECONDARY", "title": "Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26", "description": "The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.", "populationDescription": "Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent change", "timeFrame": "Day 1 (Baseline) and Week 26", "groups": [{"id": "OG000", "title": "Placebo/Sitagliptin", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}, {"id": "OG002", "title": "Canagliflozin 300 mg", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "1.4"}, {"groupId": "OG001", "value": "7.2", "spread": "1.3"}, {"groupId": "OG002", "value": "8.9", "spread": "1.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.010", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "4.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.2", "ciUpperLimit": "8.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.9"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Least-Squares Mean Difference", "paramValue": "6.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.8", "ciUpperLimit": "10.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.9"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse event data were collected for the duration of study (52 weeks).", "description": "The total number of adverse events listed in the \"Other (non-Serious) Adverse Events\" table are based upon a cut-off of greater than or equal to 5 percent of patients experiencing the adverse event in any treatment arm either during the 26-week period or entire 52-week period.", "eventGroups": [{"id": "EG000", "title": "Placebo/Sitagliptin: Baseline to Week 26", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52. Data are presented for Baseline to Week 26.", "seriousNumAffected": 5, "seriousNumAtRisk": 115, "otherNumAffected": 31, "otherNumAtRisk": 115}, {"id": "EG001", "title": "Canagliflozin 100 mg: Baseline to Week 26", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone. Data are presented for Baseline to Week 26.", "seriousNumAffected": 3, "seriousNumAtRisk": 113, "otherNumAffected": 35, "otherNumAtRisk": 113}, {"id": "EG002", "title": "Canagliflozin 300 mg: Baseline to Week 26", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone. Data are presented for Baseline to Week 26.", "seriousNumAffected": 4, "seriousNumAtRisk": 114, "otherNumAffected": 40, "otherNumAtRisk": 114}, {"id": "EG003", "title": "Placebo/Sitagliptin: Baseline to Week 52", "description": "Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52. Data are presented for Baseline to Week 52.", "seriousNumAffected": 6, "seriousNumAtRisk": 115, "otherNumAffected": 49, "otherNumAtRisk": 115}, {"id": "EG004", "title": "Canagliflozin 100 mg: Baseline to Week 52", "description": "Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone. Data are presented for Baseline to Week 52.", "seriousNumAffected": 8, "seriousNumAtRisk": 113, "otherNumAffected": 48, "otherNumAtRisk": 113}, {"id": "EG005", "title": "Canagliflozin 300 mg: Baseline to Week 52", "description": "Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone. Data are presented for Baseline to Week 52.", "seriousNumAffected": 7, "seriousNumAtRisk": 114, "otherNumAffected": 57, "otherNumAtRisk": 114}], "seriousEvents": [{"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Escherichia bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Gastrointestinal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Sepsis syndrome", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Periprosthetic fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Subdural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Spinal column stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Hypercapnia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52.", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Restrictive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Bacterial Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Bronchopneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Arteriogram coronary", "organSystem": "Investigations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Dupuytren's contracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Pelvic prolapse", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 114}]}, {"term": "Dizziness postural", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 114}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 7, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 114}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 13, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 11, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 15, "numAtRisk": 114}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 14, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 8, "numAtRisk": 114}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 9, "numAtRisk": 114}]}, {"term": "Vulvovaginal mycotic infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 114}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52. In the Week 26 study report, 2 patients had hypoglycaemia recorded in error by the investigator, which were corrected in the Week 52 study report.", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 5, "numAtRisk": 114}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 9, "numAtRisk": 114}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 10, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 7, "numAtRisk": 114}]}, {"term": "Pollakiuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 6, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 8, "numAtRisk": 114}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 114}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52.", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 114}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52.", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 6, "numAtRisk": 114}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MEDDRA 14.1 / 15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52.", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 115}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 113}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 114}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 115}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 113}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 114}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days."}, "pointOfContact": {"title": "Vice President, Franchise Medical Leader, Cardiovascular & Metabolism Franchise", "organization": "Janssen Research & Development, LLC", "phone": "1-800-526-7736"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Brazil", "Ireland", "Portugal"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000068896", "term": "Canagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}], "browseLeaves": [{"id": "M207501", "name": "Chrysarobin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M331", "name": "Canagliflozin", "asFound": "Nasopharyngeal", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}